Feasibility of multimodality therapy including extended resections in stage IVA thymoma  by Huang, James et al.
G
S
F
r
J
Jeneral Thoracic
urgeryeasibility of multimodality therapy including extended
esections in stage IVA thymoma
ames Huang, MD,a Nabil P. Rizk, MD,a William D. Travis, MD,b Venkatraman E. Seshan, PhD,c Manjit S. Bains, MD,aoseph Dycoco, BA,a Robert J. Downey, MD,a Raja M. Flores, MD,a Bernard J. Park, MD,a and Valerie W. Rusch, MDa
O
p
p
M
M
d
p
R
I
c
c
C
m
3
m
C
p
m
S
d
G
TSDr Huang
Dr Rizk
Earn CME credits at http://
cme.ctsnetjournals.orgTbjective: Extended resections for advanced-stage thymomas are not commonly
erformed because of the potential morbidity in the face of unclear survival or
alliative benefit. We reviewed our experience with multimodality treatment for
asaoka stage IVA thymomas for feasibility and outcomes.
ethods: We conducted a retrospective review of a single-institution surgical
atabase. Data included patient demographics, preoperative staging and treatment,
erioperative events, pathologic findings, and postoperative outcomes.
esults: During the period from 1996 to 2006, 18 patients who had Masaoka stage
VA thymoma underwent surgical resection. All patients received preoperative
hemotherapy. Four patients with extensive pleural involvement underwent con-
omitant extrapleural pneumonectomy and postoperative hemithoracic radiation.
omplete resection was achieved in 12 (67%) patients. There was no operative
ortality. With a median follow-up of 32.2 months (range 1.4–129.9 months),
-year, 5-year, and 10-year survivals were 91%, 78%, and 65%, respectively, and
edian survival has not yet been reached.
onclusion: Multimodality therapy including extended surgical resection can be
erformed in select patients with stage IVA thymoma with low morbidity and
ortality and can result in excellent long-term survival.
urgery is considered the mainstay of treatment for thymoma. The prognosis
in thymoma has been consistently established to correspond to the complete-
ness of resection and the Masaoka stage of the tumor.1-5 Masaoka stage IVA
escribes locally advanced disease with pleural or pericardial metastases without
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TSistant metastases. The treatment of advanced thymoma is
nclear inasmuch as complete resection may be difficult to
ttain and no standardized approach to multimodality treatment
as been developed. The literature on stage IVA thymoma has
een limited owing to its rarity, and series often span several
ecades, reflecting older histologic classification schemes,
herapeutic agents, or surgical techniques.
In stage IVA thymoma, metastatic disease confined to
he chest still allows the potential for complete resection of
ll disease. Extensive resections including extrapleural
neumonectomy (EPP) and resection of the superior vena
ava for various thoracic malignant tumors including thy-
oma have been reported.6-13 Several reports suggest tha
ultimodality therapy in advanced thymoma may improve
utcomes by potentially increasing resectability and reduc-
ng recurrences.14-19 The purpose of this study was to -
ermine the feasibility and outcome of multimodality ther-
py and extended resections in a contemporary series of
onsecutive patients with Masaoka stage IVA thymoma.
atients and Methods
ollection of Clinical Data
e undertook a retrospective review of all patients undergoing
esection for thymic epithelial tumors at Memorial Sloan–Ketter-
ng Cancer Center between January 1996 and December 2006. The
nstitutional Review Board granted approval for this study on
ugust 30, 2005. Patients who had undergone prior resection and
atients with a diagnosis of thymic carcinoma only or thymic
arcinoid were excluded from the analysis. During this time pe-
iod, 107 patients underwent surgery for the diagnosis of thymoma
r well-differentiated thymic carcinoma. Of these, 18 patients had
tage IVA thymoma with pleural dissemination and were included
n this analysis. Patient records were reviewed for demographic
nformation, treatment details, adverse events, and outcomes.
athologic Classification
icroscopic sections from these patients were re-reviewed by one
athologist (W.T.) to confirm the diagnosis of thymoma without
rior knowledge of clinical data. Histologic type was classified
ccording to the 2004 revision of the World Health Organization
lassification of thymic epithelial tumors.20 Resection status wa
Abbreviations and Acronyms
CP  carboplatin and paclitaxel
EP  cisplatin and etoposide
EPP  extrapleural pneumonectomy
PAC  cisplatin, doxorubicin, and
cyclophosphamide
RECIST Response Evaluation Criteria In Solid
Tumors
SSDI  Social Security Death Index
VIP  etoposide, ifosfamide, cisplatinetermined from the operative notes and the pathology reports. R0 p
478 The Journal of Thoracic and Cardiovascular Surgery ● Decnd R1 resections were collectively considered as complete mac-
oscopic resections. Incomplete resections were defined as those
esections in which gross tumor was left behind (R2 resections).
isease Assessment, Adverse Events, and Follow-up
esponse to preoperative therapy was graded according to the RE-
IST criteria (Response Evaluation Criteria In Solid Tumors). Partial
esponse was defined as a 30% decrease and progressive disease as a
0% increase in the longest diameter of target lesions.21 Perioperative
dverse events and adverse events arising from adjuvant radiation
herapy were identified from the medical record and graded according
o the “Common Terminology Criteria for Adverse Events” version
.0.22 A significant proportion of patients received their chemot-
py outside of this institution and, therefore, data regarding these
reatment-related adverse events were not uniformly available. Dates
f death were obtained from the medical record and from the Social
ecurity Death Index (SSDI). Surviving patients were censored at the
ast update of the SSDI on January 24, 2007. Recurrences were dated
rom the first postoperative radiographic study that demonstrated
ecurrent disease. Although there was no strict routine for postoper-
tive follow-up, the most common approach was to obtain serial
omputed tomographic scans of the chest, generally at 6-month in-
ervals. Patients with no evidence of disease were censored at the date
f the most recent radiographic study demonstrating absence of
isease.
tatistical Analysis
urvival analysis was performed by the Kaplan–Meier method and
as calculated from the date of surgery to the date of death or to
he last update of the SSDI. Disease-free survival was determined
n only those patients who had undergone complete macroscopic
esections and was calculated from the date of surgery to the date
f the first radiographic study demonstrating recurrent disease or
ost recent study demonstrating absence of disease.
esults
linical and Pathologic Data
rom January 1996 to December 2006, 18 patients with
tage IVA thymoma underwent multimodality therapy in-
luding surgery. Patient characteristics are shown in T
. The median age was 43.5 years (range 26 –74 years
atients were female. The majority of patients were white.
he most common presentations were pain or dyspnea,
lthough many patients were free of symptoms. None of the
atients had any significant cardiac, pulmonary, or renal
isease, but 1 patient had insulin-dependent diabetes. There
ere no cases of myasthenia gravis at diagnosis, although
his disease developed postoperatively in 1 patient, and 1
atient had systemic lupus erythematosus. The histologic
lassification of the tumors was distributed primarily among
he B subtypes with half of the patients demonstrating a
omponent of B3 thymoma.
reoperative Treatment
ll 18 patients received preoperative chemotherapy with a
latinum-based regimen. Treatment details are noted in
ember 2007
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G
TSable 2. The majority (n  10) underwent treatment wit
AC (cisplatin, doxorubicin, and cyclophosphamide). Three
atients each received VIP (etoposide, ifosfamide, cispla-
in), CP (carboplatin and paclitaxel), and 2 were treated with
E (cisplatin and etoposide). One patient taking CP re-
eived concurrent radiation. Three patients who failed to
espond to initial chemotherapy received additional alterna-
ive systemic therapy. There were 12 partial responses and
o complete responses, for an overall response rate to che-
otherapy of 67%.
urgical Management
he surgical management, perioperative treatment, and out-
omes are shown schematically in Figure 1. The 
ommon approach used either a hemi-clamshell (n  8)
ABLE 1. Patient characteristics (n  18 patients)
ge (y)
Median 43.5
Range 26–74
ender
Male 8
Female 10
ymptoms on presentation
Pain 6
Dyspnea 5
Cough 1
None 6
thnicity
White 15
Asian 1
Hispanic 1
African American 0
Other 1
omorbidities
Coronary disease 0
Congestive heart failure 0
Renal insufficiency 0
Chronic obstructive pulmonary disease 0
Diabetes 1
utoimmune disorders
Myasthenia gravis 0
Red cell aplasia 0
Hypogammaglobulinemia 0
Systemic lupus erythematosus 1
istology (WHO classification)
AB 1
B1 2
B2 3
B3 6
B1-B2 2
B2-B3 2
B1-B3 2
HO, World Health Organization.ncision or full clamshell (n  3) to provide adequate v
The Journal of Thoracicxposure of the mediastinum and pleural space (Table 2
cases, the clamshell incision was extended with a partial
ternotomy for better exposure of the mediastinum and
iaphragm. In 3 cases requiring a thymectomy with en bloc
PP, a median sternotomy was performed to mobilize the
hymus followed immediately by a posterolateral thoracot-
my to resect the lung and pleura. Pleural and parenchymal
nvolvement was most frequently managed with pleurec-
omy and wedge resections of involved lung. Extensive
leural involvement necessitated EPP in 4 patients, lobec-
omy in 2 patients, and pneumonectomy and parietal pleu-
ectomy in 1 patient. Local infiltration also necessitated
esection of the superior vena cava or innominate vein in 3
atients and chest wall resection in 2 patients. In patients
ith disease involving the diaphragm, this was resected and
he diaphragm either repaired primarily or reconstructed
ith prosthetic material. Complete macroscopic resection of
ll tumor was achieved in 12 (67%) patients. Resections
ere incomplete in the remaining 6 patients. Four of these
ad near-total resections, in which all of the tumor was
emoved but minimal residual disease was left behind on
ither the great vessels or the phrenic nerve. The other 2
ncomplete resections left the gross tumor behind owing to
umor invading the heart in 1 case and inaccessible bilateral
isease in the other.
ostoperative Treatment
he 4 patients who underwent EPP received adjuvant
emithoracic radiation (4500–5400 cGy). Three additional
atients were treated with postoperative mediastinal radia-
ion to the tumor bed alone (3000–5400c Gy). Five patients
ere treated with additional postoperative chemotherapy.
Table 2) Three patients had postoperative instillation
ntrapleural brachytherapy with P32 (10–15 mCi) via an
ntrapleural catheter placed at the time of the operation.
mmediate and Long-term Outcomes
here were no operative deaths and the 30-day mortality
as 0%. The median length of hospital stay was 9 days
range 5–17 days). Perioperative adverse events occurred in
 (39%) of the 18 patients and are noted in Table 
ost common events were pulmonary (n  7), followed by
astrointestinal (n  2). One patient required vocal cord
njection for a temporary laryngeal nerve dysfunction, and 1
atient who had been receiving high-dose corticosteroids
equired rewiring of an unstable sternum. There was one
ajor complication of an intraoperative cardiac arrest of
nknown etiology in a patient who was successfully resus-
itated and subsequently discharged from the hospital in 9
ays with no sequelae. Adjuvant radiation therapy was well
olerated, with adverse events limited to only grade 1 or 2
kin reactions, nausea, and esophagitis. One long-term ad-
erse event was noted in a long-term survivor (112
and Cardiovascular Surgery ● Volume 134, Number 6 1479
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G
TSonths)—radiation-induced breast cancer, which devel-
ped 8 years after postoperative hemithoracic radiation.
isease-free and Overall Survival
mong the 12 patients who had a complete macroscopic
esection, recurrences developed in 3 patients who had all
ndergone pleurectomies (5, 65, and 95 months postopera-
ively). Of the patients with recurrences, all of which were
leura-based, 1 died of disease at 73 months, 1 who had
ostoperative chemotherapy and intrapleural brachytherapy
ad 2 re-resections and is alive with disease at 77 months,
nd 1 who had postoperative radiation is alive with disease
t 117 months. One patient with an initially incomplete
esection underwent re-resection of the residual disease 3
onths postoperatively with a complete macroscopic resec-
ion and remains alive with disease at 108 months.
At the time of latest follow-up, 3 of the 18 patients had
ied at 29, 42, and 73 months. Four patients have survived
ore than 9 years. The longest survival in this series is 11
ears and the patient is free of disease. The overall survival
f these patients was 91% at 3 years, 78% at 5 years, and
5% at 10 years (Figure 2). Median survival has no
een reached. Median follow-up was 32.2 months (range
.4–129.9 months). Disease-free survival was 90% at 3 and
years and 34% at 10 years, with a median disease-free
urvival of 95 months. The median follow-up for disease
tatus was 22.8 months (range 0.2–108.7 months) (Fig
ABLE 2. Patient treatment
atient
age, sex) Histology
Preoperative
treatment Response
(33, F) B1-B3 CP PR Sterno
(56, F) B3 PAC PR Hemi-
(37, F) B2-B3 PAC PR Thora
(26, M) B1 PE  CAV Stable Hemi-
(32, F) B2 VIP  OP PR Sterno
(71, F) B1 VIP N/A Clams
(56, F) B3 PE Progressive Sterno
(41, M) B1-B2 PAC PR Hemi-
(38, F) B3 CP  PE PR Sterno
0 (41, M) B1-B3 VIP PR Hemi-
1 (53, M) B2 CP  RT PR Hemi-
2 (46, M) B1-B2 PAC PR Thora
3 (57, M) B3 PAC PR Sterno
4 (43, F) B2 PAC Stable Thora
5 (44, M) B2-B3 PAC PR Hemi-
6 (74, M) B3 PAC Stable Hemi-
7 (39, F) AB PAC Stable Sterno
8 (58, F) B3 PAC PR Hemi-
P, Carboplatin, paclitaxel; PAC, cisplatin, doxorubicin, cyclophosphamide
toposide, ifosfamide, cisplatin; OP, octreotide, prednisone; RT, radiation;). l
480 The Journal of Thoracic and Cardiovascular Surgery ● Dect
iscussion
here are few studies in the literature examining the man-
gement of stage IVA thymoma. For thymomas with in-
rathoracic metastases, the optimal treatment strategy re-
ains undefined. Previous series often have not classified
heir tumors according to the current World Health Orga-
ization histologic scheme and frequently consider stages
II and IV together collectively as advanced disease. Series
hat include patients with stage IV disease may span mul-
iple decades and do not always distinguish between resec-
ions for pleural recurrences versus thymomas with pleural
nvolvement at diagnosis. Surgery is considered the main-
tay of treatment, but few reports have gone into detail
egarding the surgical approaches to advanced thymomas
ith pleural involvement. In Masaoka’s original report,
atients with stage IV disease (including IVA and IVB) had
 5-year survival of 50% and a 10-year survival of 3
ince then, several series have observed a wide range of
urvivals for stage IVA disease (Table 4). Our prev
eries included a smaller number of patients (n  9) with
tage IVA thymomas treated less uniformly over a period of
4 years (1949 to 1993).1 This earlier experience suggeste
hat multimodality treatment and complete resection were
mportant in achieving long-term survival. We now present
larger contemporary series of patients who had Masaoka
tage IVA thymoma at diagnosis, treated more uniformly with
ultimodality treatment including extended resections with
proach
Resection
status
Postoperative
treatment Outcome
, thoracotomy Incomplete CP  RT Dead, 42 mo
shell Incomplete P32 Alive, 38 mo
y Complete N/A Alive, 130 mo
shell Complete RT Alive, 117 mo
, thoracotomy Complete RT Alive, 112 mo
Complete N/A Dead, 73 mo
, clamshell Incomplete None Alive, 21 mo
shell Complete PAC  P32 Alive, 77 mo
, clamshell Incomplete None Alive, 108 mo
shell Complete RT Dead, 29 mo
shell Incomplete CP Alive, 38 mo
y Complete RT Alive, 32 mo
Complete RT Alive, 24 mo
y Complete P32 Alive, 21 mo
shell Incomplete CP Alive, 16 mo
shell Complete None Alive, 14 mo
, thoracotomy Complete RT Alive, 4 mo
shell Complete PAC Alive, 2 mo
cisplatin, etoposide; CAV, cyclphosphamide, doxorubicin, vincristine; VIP,
p 32 brachytherapy; PR, partial response; N/A, not available.Ap
tomy
clam
cotom
clam
tomy
hell
tomy
clam
tomy
clam
clam
cotom
tomy
cotom
clam
clam
tomy
clam
; PE,ow morbidity, no mortality, and excellent long-term survival.
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G
TSComplete resections can be difficult to achieve in the
ace of a large mediastinal mass with associated pleural
isease. Resectability rates of stage IVA thymomas have
een reported to range from 0% to 42% without preopera-
ive therapy.3,17,18 Induction therapy for advanced thym-
as, including stages III and IV, has been advocated by
everal authors with good clinical response rates and im-
roved resectability rates in the range of 70%.17,19 Despite
he heterogeneity of chemotherapy regimens in our series,
ll were platinum based. Three patients who failed to re-
pond to initial chemotherapy underwent a second line of
ABLE 3. Perioperative adverse events*
dverse event
Grade
1 2 3 4 5
telectasis — 3 — — —
neumonia — 3 — — —
leural effusion — 1 — — —
leus — 1 — — —
olitis — 1 — — —
aryngeal nerve dysfunction — — 1 — —
ound complication — — 1 — —
ardiac arrest — — — 1 —cAnalyzed according to CTCAE version 3.0.22
The Journal of Thoracicreatment, and overall we observed a clinical response rate
f 67%, emphasizing that thymomas are sensitive to plati-
um-based chemotherapy. In a series of 21 stage III and
VA thymomas receiving induction therapy with PAC plus
rednisone, Kim and associates15 reported a complete re-
ection rate of 76%. We obtained comparable results in our
eries with a 67% complete resection rate in our group of
tage IVA thymomas.
We consider an aggressive approach toward surgical
esection to be warranted. The management of thymoma
ith pleural involvement depends on whether the pleural
isease is limited or extensive. Our experience suggests that
isease limited to scattered pleural metastases can be man-
ged by resection of individual pleural lesions and concom-
tant pulmonary resections as needed. There are no data
egarding the use of complete parietal pleurectomy for these
atients. Unlike malignant pleural mesothelioma, in which
he disease intrinsically involves the entire pleural surface,
etastatic thymoma may be a more limited pleural disease
rocess. In the majority of patients, a hemi-clamshell ap-
roach provides optimal exposure of the mediastinum as
ell as the pleural space.23,24
In patients with extensive and confluent pleural dis-
ase, an extended resection with EPP is required for
Figure 1. Schema showing the preoperative and
postoperative treatment, the operations per-
formed, and the outcomes in the 18 patients
undergoing surgery for stage IVA thymoma. RT,
Radiation; NED, alive, no evidence of disease;
AWD, alive with disease; DOD, dead of disease
*One patient also received concurrent induction
radiation. **One patient received concurrent
chemoradiation postoperatively..omplete resection. A median sternotomy followed im-
and Cardiovascular Surgery ● Volume 134, Number 6 1481
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G
TSediately by en bloc EPP via a posterolateral thoracot-
my usually provides the best exposure. Compared with
he largest published experience with EPP, our series had
ess morbidity and no mortality.25 Our results are com-
arable with a previously reported small series of EPP for
hymoma and add to the literature that suggests aggres-
ive approaches with extended resections are feasible
ith low morbidity and mortality.26,27 This may relate t
he generally young age and good overall health of pa-
ients with thymoma.
ABLE 4. Survival of patients with stage IVA thymoma
irst author Year n
Five-year
survival (%)
Ten-year
survival (10%)
asaoka3* 1981 11 50 0
akahara7* 1988 15 47 47
aggi17 1991 21 59 40
an30* 1994 12 41 22
lumberg1 1995 9 100 —
egnard31* 1996 19 — 30
agi12 1996 5 67 33
ilkins32* 1999 5 40 40
ondo2 2003 67 70 47
akagawa4* 2003 11 47 47
perling5* 2003 10 48 16
ucchi16 2005 16 — 46
right26 2006 5 75 50
SKCC (current
series)
2007 18 78 65oSKCC, Memorial Sloan–Kettering Cancer Center. *Stage IVA  B.
482 The Journal of Thoracic and Cardiovascular Surgery ● DecHigh-dose hemithoracic radiation has been shown to be
easible after EPP for mesothelioma and reduces local re-
urrence rates.28,29 The absence of the lung in the c
llows delivery of higher doses of radiation without incur-
ing additional toxicity. Drawing from this experience, we
ave treated all 4 patients who underwent EPP with
emithoracic radiation at a median dose of 5040 cGy. Three
ther patients received adjuvant mediastinal radiation, 2 in
he setting of microscopic diseased margins. There was no
ajor immediate radiotherapy-related toxicity. However, a
adiation-induced second malignant tumor in 1 long-term
urvivor (breast cancer arising on the irradiated side 8 years
ostoperatively) serves as a cautionary note that all of these
atients should be kept under life-long follow-up. The role
f adjuvant radiation after pleurectomy and the role of
djuvant chemotherapy remain unclear. Currently no data
ave been reported regarding the feasibility and efficacy of
djuvant chemotherapy in this setting.
In conclusion, multimodality therapy of stage IVA
hymoma incorporating extended resections is feasible
nd safe with low morbidity and mortality and offers the
otential for long-term survival. However, by definition,
ny retrospective single-institution surgical series will
nclude small numbers of patients who never underwent
n operation because induction therapy failed. In addi-
ion, there is a need to develop more uniform treatment
egimens for this challenging patient population. Our
ata suggest that prospective multicenter trials in this
atient population are warranted to confirm and extend
Figure 2. Overall and disease-free
survival.ur experience.
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iscussion
r Cameron D. Wright (Boston, Mass). Thank you, Dr Huang.
hat was an excellent presentation. The paper was likewise clear,
oncise, and quite informative.
The authors describe a relatively modern cohort of patients
ith locally advanced thymomas, those with stage IVA disease,
reated in a fashion relatively similarly, and we all recognize there
s no true standard therapy for these particular patients. After
eceiving induction chemotherapy, these 18 patients had a high
omplete resection rate, minimal morbidity, and no mortality. The
urvival was quite good at 78% at 5 years. I have a note of caution,
hough. The median follow-up was only 32 months, and these
umors do have an ability to recur more than 5 years after resec-
ion. Therefore, this information is somewhat guarded. The authors
onclude that induction chemotherapy followed by resection is
afe and efficacious and probably represents the appropriate ther-
py.
I have 5 questions for the authors. First, was there any hint as
o which chemotherapy was the best? PAC was the most common.
hat is certainly very popular. Did you have any inkling that that
ight be the best chemotherapy for this particular disease? Give us
he benefit of your experience.
Second, are there any patients on whom you do not operate
ith stage IVA disease? You told us those on whom you do
perate, but not those on whom you do not.
Third, how extensive should the pleurectomy be? Should we
ust do local pleural resection of the grossly visible metastases or
and Cardiovascular Surgery ● Volume 134, Number 6 1483
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TShould we do a complete pleurectomy when we identify even one
r two pleural metastases?
Fourth, were there any near-complete responses radiographi-
ally or, even more importantly, pathologically, and was there any
vidence of necrosis in your pathologic specimens from this in-
uction chemotherapy, signifying some benefit for this chemother-
py?
Finally, why not give chemotherapy postoperatively to the
atients who responded preoperatively? Sixty-seven percent re-
ponded preoperatively. You identified that biologically. It is an
ggressive tumor that has already metastasized. Why not give
ore chemotherapy to those who have proven to have had some
enefit?
Dr Huang. Thank you, Dr Wright. The most frequent combi-
ation of chemotherapy used in our series was PAC based on the
references of the treating oncologist as well as data from Loehrer
nd associates1,2 demonstrating the efficacy of this combination
ell as its superiority to alternative regimens such as cisplatin and
toposide and ifosfamide.
As this was a retrospective review of a surgical database, this
tudy includes only those patients who underwent resection. Pa-
ients with stage IVA disease who may not have responded to
nduction therapy or who were otherwise not deemed to be surgical
andidates were not included in this analysis; therefore, no con-
lusions can be drawn regarding contraindications to surgery.
The consensus among the surgeons in our group is to do a local
esection of each individual pleural lesion, with the goal of attain-
ng a complete resection while limiting the amount of pulmonary
esection needed. We generally do not perform a complete parietal
leurectomy. In cases in which the pleural component is very
xtensive and confluent, EPP may offer the only possibility of
chieving a complete resection.
Although there were no radiographic complete responses based
n the RECIST criteria, 5 of the 10 responders did have evidence
f treatment effect ranging up to 50% necrosis in the specimens,
onfirming the chemosensitivity of this tumor. There were no
athologic complete responses, re-emphasizing the point that med-
cal therapy alone is probably insufficient and that surgery remains
ssential in the treatment of thymoma.
Although several reports have demonstrated the efficacy of
nduction chemotherapy, there are no data regarding the utility of
ostoperative chemotherapy in thymoma. It is reasonable to con-
ider postoperative chemotherapy in patients with incomplete re-
ections who responded to induction therapy. Whether postopera-
ive chemotherapy is of any benefit to patients with complete
esections is unknown.
484 The Journal of Thoracic and Cardiovascular Surgery ● DecDr Federico Venuta (Rome, Italy) What was the reason for
ncompleteness of resection? Was it related to the primary tumor
r to the pleural dissemination? Were there patients with pleural
ffusions in the population of patients receiving pleurectomy?
robably it was my fault, but I did not get the survival of patients
eceiving incomplete resections.
Dr Huang. In 4 of the 6 incomplete resections, only minimal
isease was left behind owing to involvement of either the great
essels or both phrenic nerves. In each of these 4 cases, tumor was
haved off the critical involved structures, necessarily leaving
inimal residual disease behind. In the other 2 incomplete resec-
ions, gross disease remained owing to invasion of the heart in 1
ase and the discovery of bilateral pleural disease in the other. Data
egarding pleural effusions were not captured in our database.
There was a trend toward a survival benefit for complete
esection. The survival was 86% in macroscopically complete
esections and 50% in those with incomplete resections. However,
ith only 3 events, these numbers are not statistically significant.
Dr Philip Linden. (Boston, Mass) Did you make any effort to
etermine what preoperative factors might influence long-term
urvival; that is, did the degree of response to chemotherapy
orrelate with survival, comorbid conditions, or type of operation
t all? It would be very useful to know to try to predict which
atients might do well long term.
Dr Huang. This cohort clearly represents a preselected group
f patients. In general, these were very young and otherwise
ealthy patients with very little comorbidity. The small number of
atients in this cohort precluded the performance of a multivariate
nalysis of prognosticating factors.
Dr Walter Weder. (Zurich, Switzerland) What was the sur-
ival difference between those who underwent EPP compared with
leurectomy?
Dr Huang. With only 3 events for analysis, there was a
arginally better survival for pleurectomy than EPP that was not
tatistically significant.
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